ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Development and Operating ...
Freshpet, Inc. to Report First Quarter 2026 Results on Wednesday, May 6, 2026 BEDMINSTER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (Nasdaq: FRPT) (“Freshpet” or the “Company”) today announced it will report results for the first quarter ended March 31, 2026 on Wednesday, May 6, 2026 before market open. The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 8:00 a.m. ET on Wednesday, May 6, 2026. To participate on the live call, listener...
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effectiv...
A director at NextDecade Corp bought 71,500 shares at 7.070USD and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
A director at New Mountain Finance Corp bought 500,000 shares at 8.050USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evor...
Freshpet, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Full Year 2025 Net Sales Growth of 13% and Achieves Positive Free Cash Flow Provides Full Year 2026 Outlook BEDMINSTER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $285.2 million, an increase of 8.6%.Gross margin of 43.3%, compared to the prior year period of 42.5%.Adjusted Gross ...
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit Format: One-o...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results pre...
Freshpet, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) BEDMINSTER, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that the Compensation and Human Capital Management Committee of its Board of Directors approved an equity award as an inducement material to John O’Connor’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). In connection with his previously announced appointment as Chief Financial Officer, Mr. O’Connor was granted, effective February 9, 2026,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.